MedTrace Logo

Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease

NCT01233570 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-11-03

No results posted yet for this study

Summary

An assessment of the efficacy of topical tacrolimus in the treatment of cutaneous crohns disease

Conditions

  • Crohn Disease

Interventions

DRUG

Tacrolimus

Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension

Sponsors & Collaborators

  • University of Aberdeen

    lead OTHER

Principal Investigators

  • Anthony D Ormerod, MBChB · University of Aberdeen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01233570 on ClinicalTrials.gov